Impact of NCD guidelines on Medicare patients with chemotherapy-induced anemia receiving erythropoiesis-stimulating agents: Results from a community oncology practice

Community Oncology

Volumn 6, Issue 6, 2009, Pages 257-261

  Feinberg, Bruce ^a   Gilmore, James ^a   Gondesen, Tom ^a   Jackson, James H ^b   Saleh, Mansoor ^a  

^a Georgia Cancer Specialists   (United States)

^b XCENDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; ANTINEOPLASTIC AGENT; HEMOGLOBIN;

AGED; ANEMIA; ARTICLE; BLOOD TRANSFUSION; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED ANEMIA; CONTROLLED STUDY; DRUG INDUCED DISEASE; ELECTRONIC MEDICAL RECORD; FEMALE; FOLLOW UP; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICARE; PRACTICE GUIDELINE; QUALITY OF LIFE;

EID: 67649383675     PISSN: 15485315     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1548-5315(11)70349-7     Document Type: Article

References (21)

1. American Cancer Society. Cancer facts & figures, 2008. Available at: http://www.cancer.org/downloads/STT/2008CAFFfinalsecured.pdf. Accessed February 26, 2009.
2. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999;91:1616-1634. (Pubitemid 29479929)
3. Balducci L. Epidemiology of anemia in the elderly: information on diagnostic evaluation. J Am Geriatr Soc 2003;51(3 suppl):S2-S9. (Pubitemid 36356346)
4. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment [published erratum]. J Natl Cancer Inst 2000;92:497.
5. Berndt E, Kallich J, McDermott A, Xu X, Lee H, Glaspy J. Reductions in anaemia and fatigue are associated with improvements in productivity in cancer patients receiving chemotherapy. Pharmacoeconomics 2005;23:505-514. (Pubitemid 40994138)
6. Procrit [package insert]. Raritan, NJ: Ortho Biotech Products, LP; 2008.
7. Aranesp [package insert]. Thousand Oaks, CA: Amgen, Inc; 2008.
8. Rizzo JD, Lichtin AE, Woolf SH, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 2002;20:4083-4107.
9. Waltzman RJ, Croot C, Justice GR, et al. Randomized comparison of epoetin alfa (40,000 U weekly) and darbepoetin alfa (200 μg every 2 weeks) in anemic patients with cancer receiving chemotherapy. Oncologist 2005;10:642-650.
10. Witzig TE, Silberstein PT, Loprinzi CL, et al. Phase III, randomized, double-blind study of epoetin alfa versus placebo in anemic patients with cancer undergoing chemotherapy. J Clin Oncol 2005;23:2606-2617. (Pubitemid 46179449)
11. Steensma D, Molina R, Sloan J, et al. Phase III study of two different dosing schedules of erythropoietin in anemic patients with cancer. J Clin Oncol 2006;24(7):1079-1089. (Pubitemid 46638805)
12. Centers for Medicare & Medicaid Services. Proposed decision memo for erythropoiesis stimulating agents (ESAs) for non-renal disease indications (CAG-00383N). www.cms.hhs.gov/mcd/viewdraftdecisionmemo.asp?from2= viewdraftdecisionmemo.asp&id=203&. Accessed May 12, 2009.
13. Centers for Medicare & Medicaid Services. Decision memo for erythropoiesis stimulating agents (ESAs) for non-renal disease indications (CAG-00383N). www.cms.hhs.gov/mcd/viewdecisionmemo.asp?from2=viewdecisionmemo. asp&id=203&. Accessed May 12, 2009.
14. Gosselin A, Pashos CL, Harley C, Mark TL, McKenzie RS. Drug administration frequency and provider office visit patterns for oncology patients during treatment with erythropoietic agents: an analysis of four observational studies. Clin Ther 2006;28:1701-1708. (Pubitemid 44856693)
15. American Society of Hematology. Policy & practice news: ASH-ASCO 2007 clinical practice guideline update on the use of epoetin and darbepoetin released. www.hematology.org/policy/news/10222007.cfm. Accessed May 12, 2009.
16. Rizzo JD, Somerfield MR, Hagerty KL, et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update. Blood 2008;111:25-41.
17. Food and Drug Administration Center for Drug Evaluation and Research (FDA CDER). Information on ESAs Update. www.fda.gov/cder/drug/infopage/RHE/default. htm. Accessed May 12, 2009.
18. Larholt K, Burton T, Hoaglin D, et al. Transfusion outcomes in erythropoiesis-stimulating agent (ESA)-treated cancer chemotherapy patients based on achieved hemoglobin (Hb) levels. J Clin Oncol 2008;26:6637.
19. Burton T, Larholt K, Pashos CL, et al. Transfusion outcomes among oncology patients initiated with erythropoiesis-stimulating agents (ESAs) at baseline (BL) hemoglobin (Hb) of <10 versus 10-11 g/dL: observational data from the dosing and outcomes study of erythropoiesis-stimulating therapies (DOSE) registry. J Clin Oncol 2008;26:20637.
20. Hess G, Nordyke RJ, Pirolli M, Hulnick S, Curry A, Gesme D. Effect of changes in labeling and reimbursement on use of ESAs and transfusions. J Clin Oncol 2008;26:20589.
21. Naeim A, Glaspy J. Changes in RBC supportive medications and transfusions in cancer patients undergoing chemotherapy before and after FDA and Medicare actions in 2007. J Clin Oncol 2008;26:20595.